Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 30
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Rocket Pharmaceuticals Inc
RCKT
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$2.54
-0.04
-1.55%
Ult. Agg.: Oct 29, 7:53 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Rocket Pharmaceuticals Financials
Rocket Pharmaceuticals (RCKT) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Rocket Pharmaceuticals Q2 Adj. EPS $(0.37) Misses $0.24 Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $0.24 by 254.17 percent. This is a 40.32 percent increase over losses of $(0.62) per
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q1 EPS $(0.42) Beats $(0.43) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.43) by 2.33 percent. This is a 25 percent increase over losses of $(0.56) per share
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q4 EPS $(0.38) Beats $(0.44) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.44) by 13.04 percent. This is a 38.71 percent increase over losses of $(0.62) per share
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q3 EPS $(0.45) Beats $(0.52) Estimate
Benzinga Newsdesk
PRO
Rocket Pharmaceuticals Q2 EPS $(0.62) Misses $(0.56) Estimate
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.56) by 10.91 percent. This is a 16.22 percent increase over losses of $(0.74) per
Benzinga Newsdesk
Dow Surges Over 600 Points; US Durable Goods Orders Fall in April
Avi Kapoor
